◎ Sugi Atlas

Atlas / Drug / Panitumumab

Panitumumab

drug
On this page

Also known as AbenixABX-EGFE7.6.3L01xc08Vectibix

Summary

Panitumumab (CHEMBL1201827) is an approved antibody (ATC L01FE02) targeting EGFR; indicated across 38 conditions including colorectal adenocarcinoma and neoplasm; with CIViC clinical evidence for 96 variant-indication associations (e.g. KRAS G12C in colorectal cancer).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Antibody
  • ATC class: L01FE02
  • Targets: 1 (EGFR)
  • Indications: 38 conditions
  • Clinical trials: 217
  • Precision-oncology evidence (CIViC): 96 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1201827
NamePanitumumab
TypeAntibody
Max phase4
ATCL01FE02

Also known as: Abenix, ABX-EGF, E7.6.3, L01xc08, Panitumumab, Vectibix, PANITUMUMAB

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

GeneTargetActionpAffinityCancer dependencyUniProt
EGFRepidermal growth factor receptorAntagonist10.317.5%P00533

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): EGFR.

Top Reactome pathways

37 total, by targets touching each:

PathwayTargetsGenes
Signaling by ERBB21EGFR
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants1EGFR
Signaling by ERBB41EGFR
SHC1 events in ERBB2 signaling1EGFR
PLCG1 events in ERBB2 signaling1EGFR
PIP3 activates AKT signaling1EGFR
Signaling by EGFR1EGFR
GRB2 events in EGFR signaling1EGFR
GAB1 signalosome1EGFR
SHC1 events in EGFR signaling1EGFR
EGFR downregulation1EGFR
GRB2 events in ERBB2 signaling1EGFR
PI3K events in ERBB2 signaling1EGFR
EGFR interacts with phospholipase C-gamma1EGFR
EGFR Transactivation by Gastrin1EGFR
Constitutive Signaling by Aberrant PI3K in Cancer1EGFR
Signal transduction by L11EGFR
Constitutive Signaling by EGFRvIII1EGFR
Inhibition of Signaling by Overexpressed EGFR1EGFR
RAF/MAP kinase cascade1EGFR
ERBB2 Regulates Cell Motility1EGFR
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling1EGFR
ERBB2 Activates PTK6 Signaling1EGFR
Cargo recognition for clathrin-mediated endocytosis1EGFR
Clathrin-mediated endocytosis1EGFR
PTK6 promotes HIF1A stabilization1EGFR
Downregulation of ERBB2 signaling1EGFR
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors1EGFR
Extra-nuclear estrogen signaling1EGFR
NOTCH3 Activation and Transmission of Signal to the Nucleus1EGFR

Dominant GO biological processes

GO termTargets
cell morphogenesis1
ossification1
embryonic placenta development1
positive regulation of protein phosphorylation1
hair follicle development1
ubiquitin-dependent protein catabolic process1
signal transduction1
cell surface receptor signaling pathway1
epidermal growth factor receptor signaling pathway1
salivary gland morphogenesis1
learning or memory1
positive regulation of cell population proliferation1
gene expression1
protein ubiquitination1
cerebral cortex cell migration1

Indications & clinical

Indications

38 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
colorectal adenocarcinoma4MONDO:0005008EFO:0000365
neoplasm4MONDO:0005070EFO:0000616
colorectal neoplasm4MONDO:0005335EFO:0004142
colorectal carcinoma4MONDO:0024331EFO:1001951
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
squamous cell carcinoma3MONDO:0005096EFO:0000707
head and neck cancer3MONDO:0005627EFO:0006859
colonic neoplasm3MONDO:0005401MONDO:0021063
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
carcinoid syndrome2MONDO:0100347EFO:1000852
non-small cell lung carcinoma2MONDO:0005233EFO:0003060
rectal cancer2MONDO:0006519EFO:1000657
carcinoma2MONDO:0004993EFO:0000313
gastric adenocarcinoma2MONDO:0005036EFO:0000503
renal cell carcinoma2MONDO:0005086EFO:0000681
carcinoma of esophagus2MONDO:0019086EFO:0002916
cholangiocarcinoma2MONDO:0019087EFO:0005221
esophageal squamous cell carcinoma2MONDO:0005580EFO:0005922
fallopian tube neoplasm2MONDO:0021092MONDO:0002158
breast neoplasm2MONDO:0021100MONDO:0007254
ovarian cancer2MONDO:0008170MONDO:0008170
lung neoplasm2MONDO:0021117MONDO:0008903
ovarian carcinoma2MONDO:0005140EFO:0001075
triple-negative breast carcinoma2MONDO:0005494EFO:0005537
breast carcinoma2MONDO:0004989EFO:0000305
biliary tract neoplasm2MONDO:0005304EFO:0003891
malignant pancreatic neoplasm2MONDO:0009831EFO:1000359
gallbladder neoplasm2MONDO:0021253MONDO:0005411
kidney cancer1MONDO:0002367MONDO:0002367
brain neoplasm1MONDO:0021211EFO:0003833
brain cancer1MONDO:0001657MONDO:0001657
glioma1MONDO:0021042MONDO:0100342

6 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 217.

Phase distribution

PhaseTrials
PHASE2144
PHASE324
PHASE121
PHASE1/PHASE220
Not specified5
PHASE41
PHASE2/PHASE31
EARLY_PHASE11

Top trials by phase / activity

NCTPhaseStatusTitle
NCT02301962PHASE4UNKNOWNPhase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
NCT02885753PHASE3RECRUITINGSystemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver
NCT03635021PHASE3ACTIVE_NOT_RECRUITINGStudy to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
NCT05863195PHASE3RECRUITINGTesting Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT06252649PHASE3RECRUITINGStudy of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06490536PHASE3RECRUITINGThe Sagittarius Trial
NCT06509126PHASE3RECRUITINGIntermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer
NCT06998940PHASE3RECRUITINGStudying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
NCT00113763PHASE3COMPLETEDEvaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
NCT00115765PHASE3COMPLETEDPACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study
NCT00339183PHASE3COMPLETEDComparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone
NCT00364013PHASE3COMPLETEDPRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy
NCT00389870PHASE3COMPLETEDIrinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil
NCT00647530PHASE2/PHASE3UNKNOWNFluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery
NCT00820248PHASE3COMPLETEDRadiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer
NCT00824785PHASE3TERMINATEDREAL3 Trial of Efficacy of EOX With/Without Panitumumab in Previously Untreated Adv OG Cancer
NCT01001377PHASE3COMPLETEDASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
NCT01142414PHASE3WITHDRAWNChemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
NCT01412957PHASE3COMPLETEDComparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer
NCT01627379PHASE3TERMINATEDCisplatin and 5-FU +/- Panitumumab for Patients With Nonresectable,Advanced or Metastatic Esophageal Squamous Cell Cancer
NCT02394795PHASE3COMPLETEDPanitumumab and RAS, Diagnostically-useful Gene Mutation for mCRC
NCT02818725PHASE3COMPLETEDI-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations
NCT03231722PHASE3COMPLETEDFirst Line mFOLFOXIRI + PANITUMUMAB vs mFOLFOX + PANITUMUMAB IN RAS AND BRAF WT METASTATIC COLORECTAL CANCER PATIENTS
NCT03300609PHASE3TERMINATED5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab
NCT04342676PHASE3COMPLETEDLymph Node Ratio and Kras Mutation in R Colon Cancer
NCT05198934PHASE3COMPLETEDSotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
NCT02876107PHASE2ACTIVE_NOT_RECRUITINGCarboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
NCT02925234PHASE2RECRUITINGThe Drug Rediscovery Protocol (DRUP Trial)
NCT02980510PHASE2ACTIVE_NOT_RECRUITINGComparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients
NCT03087071PHASE2ACTIVE_NOT_RECRUITINGPanitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
NCT03384238PHASE1/PHASE2RECRUITINGPanitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT03510208PHASE1/PHASE2RECRUITINGPanitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
NCT03983993PHASE2ACTIVE_NOT_RECRUITINGNiraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
NCT04034173PHASE2NOT_YET_RECRUITINGOptimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation
NCT04117945PHASE2ACTIVE_NOT_RECRUITINGRegorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer
NCT04587128PHASE2ACTIVE_NOT_RECRUITINGEarly-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC
NCT04787341PHASE2ACTIVE_NOT_RECRUITINGPAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence
NCT05007132PHASE2RECRUITINGTrifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
NCT05121038PHASE1/PHASE2ACTIVE_NOT_RECRUITINGCEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab
NCT05423197PHASE2NOT_YET_RECRUITING89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC

Clinical evidence (CIViC)

Variant × indication × effect (96 predictive associations from 115 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
KRAS G12CColorectal CancerSensitivity/ResponseSotorasib + PanitumumabCIViC AEID12264
KRAS WildtypeColorectal CancerSensitivity/ResponseChemotherapy + PanitumumabCIViC AEID11264
NRAS WildtypeColorectal CancerSensitivity/ResponseChemotherapy + PanitumumabCIViC AEID11270
KRAS MutationColorectal CancerResistanceCetuximab + PanitumumabCIViC AEID5345
NRAS MutationColorectal CancerResistancePanitumumab + CetuximabCIViC AEID5344
BRAF V600EColorectal CancerSensitivity/ResponsePanitumumab + VemurafenibCIViC BEID1413 +1
AREG ExpressionColorectal CancerSensitivity/ResponsePanitumumabCIViC BEID1020
BRAF Class 2 MutationsColorectal CancerSensitivity/ResponseCetuximab + PanitumumabCIViC BEID7574
BRAF Class 3 MutationsColorectal CancerSensitivity/ResponseCetuximab + PanitumumabCIViC BEID7575
BRAF MutationColorectal CancerSensitivity/ResponsePanitumumab + CetuximabCIViC BEID1404
BRAF V600EColorectal CancerSensitivity/ResponsePanitumumab + Dabrafenib + TrametinibCIViC BEID6123
BRAF V600EColorectal AdenocarcinomaSensitivity/ResponseTrametinib + PanitumumabCIViC BEID6124
CDKN2A p16 ExpressionHead And Neck Squamous Cell CarcinomaSensitivity/ResponsePanitumumabCIViC BEID753
EGFR AmplificationColorectal CancerSensitivity/ResponseCetuximab + PanitumumabCIViC BEID854
EGFR ExpressionColorectal CancerSensitivity/ResponsePanitumumabCIViC BEID1708
EREG EXPRESSIONColorectal CancerSensitivity/ResponsePanitumumabCIViC BEID1021
EGFR G465RColorectal CancerResistancePanitumumab + CetuximabCIViC BEID7083 +1
PIK3CA H1047RColorectal CancerResistanceCetuximab + PanitumumabCIViC BEID258 +1
BRAF V600Colorectal CancerResistancePanitumumabCIViC BEID88
BRAF V600EColorectal CancerResistancePanitumumab + CetuximabCIViC BEID2115
BRAF V600EColorectal CancerResistanceCetuximab + PanitumumabCIViC BEID816
CDKN2A p16 ExpressionHead And Neck Squamous Cell CarcinomaResistancePanitumumabCIViC BEID696
EGFR F404IColorectal CancerResistancePanitumumab + CetuximabCIViC BEID7099
EGFR F404VColorectal CancerResistanceCetuximab + PanitumumabCIViC BEID7100
EGFR G465EColorectal CancerResistanceCetuximab + PanitumumabCIViC BEID7084
EGFR G465VColorectal CancerResistancePanitumumab + CetuximabCIViC BEID7085
EGFR I462KColorectal CancerResistancePanitumumab + CetuximabCIViC BEID7079
EGFR I462RColorectal CancerResistanceCetuximab + PanitumumabCIViC BEID7080
EGFR I491KColorectal CancerResistanceCetuximab + PanitumumabCIViC BEID7090
EGFR I491RColorectal CancerResistancePanitumumab + CetuximabCIViC BEID7091

+66 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

158 molecules share ≥1 primary target. Top 60 by shared-target count:

MoleculeSourceStatusShared targets
AFATINIBChEMBL + PubChemPhase 4 (approved)EGFR
SELUMETINIBChEMBL + PubChemPhase 4 (approved)EGFR
ABEMACICLIBChEMBLPhase 4 (approved)EGFR
ACALABRUTINIBChEMBLPhase 4 (approved)EGFR
AFATINIB DIMALEATEChEMBLPhase 4 (approved)EGFR
ALECTINIBChEMBLPhase 4 (approved)EGFR
ASTEMIZOLEChEMBLPhase 4 (approved)EGFR
AXITINIBChEMBLPhase 4 (approved)EGFR
BACITRACINChEMBLPhase 4 (approved)EGFR
BITHIONOLChEMBLPhase 4 (approved)EGFR
BOSUTINIBChEMBLPhase 4 (approved)EGFR
BRIGATINIBChEMBLPhase 4 (approved)EGFR
CABOZANTINIBChEMBLPhase 4 (approved)EGFR
CERITINIBChEMBLPhase 4 (approved)EGFR
CHLORPROMAZINEChEMBLPhase 4 (approved)EGFR
CHROMIC CHLORIDEChEMBLPhase 4 (approved)EGFR
CISPLATINChEMBLPhase 4 (approved)EGFR
CLOTRIMAZOLEChEMBLPhase 4 (approved)EGFR
COLISTINChEMBLPhase 4 (approved)EGFR
CRIZOTINIBChEMBLPhase 4 (approved)EGFR
DACOMITINIBChEMBLPhase 4 (approved)EGFR
DASATINIBChEMBLPhase 4 (approved)EGFR
DOBUTAMINEChEMBLPhase 4 (approved)EGFR
DOCETAXELChEMBLPhase 4 (approved)EGFR
EBASTINEChEMBLPhase 4 (approved)EGFR
ECONAZOLEChEMBLPhase 4 (approved)EGFR
ERLOTINIBChEMBLPhase 4 (approved)EGFR
FEDRATINIBChEMBLPhase 4 (approved)EGFR
FLUPHENAZINEChEMBLPhase 4 (approved)EGFR
GEFITINIBChEMBLPhase 4 (approved)EGFR
GENTIAN VIOLETChEMBLPhase 4 (approved)EGFR
GILTERITINIBChEMBLPhase 4 (approved)EGFR
HEXACHLOROPHENEChEMBLPhase 4 (approved)EGFR
IBRUTINIBChEMBLPhase 4 (approved)EGFR
IMATINIBChEMBLPhase 4 (approved)EGFR
LAPATINIBChEMBLPhase 4 (approved)EGFR
LAPATINIB DITOSYLATEChEMBLPhase 4 (approved)EGFR
LAZERTINIBChEMBLPhase 4 (approved)EGFR
LEVODOPAChEMBLPhase 4 (approved)EGFR
LORLATINIBChEMBLPhase 4 (approved)EGFR
METHYLDOPAChEMBLPhase 4 (approved)EGFR
MICONAZOLEChEMBLPhase 4 (approved)EGFR
MIDOSTAURINChEMBLPhase 4 (approved)EGFR
MITOXANTRONEChEMBLPhase 4 (approved)EGFR
MOBOCERTINIBChEMBLPhase 4 (approved)EGFR
MONTELUKASTChEMBLPhase 4 (approved)EGFR
NELFINAVIRChEMBLPhase 4 (approved)EGFR
NERATINIBChEMBLPhase 4 (approved)EGFR
NICLOSAMIDEChEMBLPhase 4 (approved)EGFR
OLMUTINIBChEMBLPhase 4 (approved)EGFR
OSIMERTINIBChEMBLPhase 4 (approved)EGFR
PERHEXILINEChEMBLPhase 4 (approved)EGFR
PONATINIBChEMBLPhase 4 (approved)EGFR
SORAFENIBChEMBLPhase 4 (approved)EGFR
SULOCTIDILChEMBLPhase 4 (approved)EGFR
SUNITINIBChEMBLPhase 4 (approved)EGFR
TAMOXIFENChEMBLPhase 4 (approved)EGFR
TERFENADINEChEMBLPhase 4 (approved)EGFR
THIORIDAZINEChEMBLPhase 4 (approved)EGFR
TRIBROMSALANChEMBLPhase 4 (approved)EGFR

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 30

This page pulls from 30 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclingen_dosageclinical_trialsdepmapefoensemblentrezgogoparentgtopdbgtopdb_interactiongtopdb_ligandhgncmeshmondomsigdbpatent_compoundpharmgkbpharmgkb_guidelinepubchempubchem_activityreactomereactomeparentrefseqtranscriptuniprot